SIOX Sio Gene Therapies Inc

Price (delayed)

$2.14

Market cap

$125.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.08

Enterprise value

$45.93M

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has dropped by 93% year-on-year
The company's quick ratio has surged by 58% QoQ

Key stats

What are the main financial stats of SIOX
Market
Shares outstanding
58.75M
Market cap
$125.73M
Enterprise value
$45.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$44.53M
EBITDA
-$41.63M
Free cash flow
-$54.51M
Per share
EPS
-$1.08
Free cash flow per share
-$1.03
Book value per share
$1.84
Revenue per share
$0
TBVPS
$1.88
Balance sheet
Total assets
$98.96M
Total liabilities
$9.94M
Debt
$1.23M
Equity
$89.03M
Working capital
$88.08M
Liquidity
Debt to equity
0.01
Current ratio
10.84
Quick ratio
9.95
Net debt/EBITDA
1.92
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-53.3%
Return on equity
-65.6%
Return on invested capital
-997.8%
Return on capital employed
-49.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SIOX stock price

How has the Sio Gene Therapies stock price performed over time
Intraday
0%
1 week
-13.01%
1 month
-12.65%
1 year
-32.49%
YTD
-23.02%
QTD
-18.01%

Financial performance

How have Sio Gene Therapies's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$46.04M
Net income
-$45.74M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 31% YoY and by 6% from the previous quarter
SIOX's net income is up by 30% year-on-year and by 7% since the previous quarter

Growth

What is Sio Gene Therapies's growth rate over time

Valuation

What is Sio Gene Therapies stock price valuation
P/E
N/A
P/B
1.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 55% YoY and by 28% QoQ
The price to book (P/B) is 83% lower than the 5-year quarterly average of 7.0 and 35% lower than the last 4 quarters average of 1.8
The equity has grown by 28% since the previous quarter

Efficiency

How efficient is Sio Gene Therapies business performance
The ROE has soared by 73% YoY and by 35% from the previous quarter
SIOX's return on invested capital has surged by 58% since the previous quarter but it is down by 9% year-on-year
The company's return on assets rose by 30% YoY and by 22% QoQ

Dividends

What is SIOX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SIOX.

Financial health

How did Sio Gene Therapies financials performed over time
The total assets has soared by 134% YoY and by 24% from the previous quarter
Sio Gene Therapies's total liabilities has shrunk by 73% YoY
The debt is 99% smaller than the equity
SIOX's debt to equity has dropped by 100% year-on-year
The debt has dropped by 93% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.